CV Lattes
ORCID
Google Scholar Citations
Universidade de São Paulo (USP). Instituto de Ciências Biomédicas (ICB) (Institutional affiliation from the last research proposal) Birthplace: Brazil
I am currently working at the Department of Microbiology at the Institute of Biomedical Science (ICB) of the University of São Paulo (since 07/2014). I have a Ph.D. in Molecular Biophysics from the State University of São Paulo (2007) and Postdoctoral training at the University of Cambridge under the supervision of Tom Blundell (2007-2011). I was a Young Research Fellow at LNBio (Campinas-SP) (2012-2014). I am a biologist from the State University of São Paulo. I have experience in biochemistry, focused on protein biochemistry (structural biology), structure-based drug discovery, protein targets of Mycobacterium tuberculosis, and natural products biosynthesis. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Buturison is an aminoglycoside produced by Niallia circulans, which has a unique structure among this group of antibiotics due to the presence of a (2S)-4-amino-2-hydroxybutyril moiety linked to the 2-deoxystreptamine aglycone C1 carbon. This modification in aminoglycosides is particularly interesting, as it confers butirosin insensitivity to a group of proteins called aminoglycoside-modi…
Infectious diseases are one of the major problems of the current public and worldwide health. Although much has been released about infectious caused by bacteria, those infectious diseases caused by invasive fungi are also alarming and lead to the death of a high number of patients, particularly those from hospital environments or those suffering from immunodeficiency. Furthermore, there …
Tuberculosis is an infectious disease caused predominantly by Mycobacterium tuberculosis and leads to the death of more than a million people every year worldwide. The treatment of tuberculosis consists of the use of four different antimicrobials for at least six months. Although antimicrobial resistance mechanisms in tuberculosis do not involve horizontal transfer, mutations in responsib…
(Only some records are available in English at this moment)
Tuberculosis is one of the major infectious diseases that afflict humankind, which causes the death of about a million people worldwide. Because of the intensive use of antimicrobials in the treatment of this disease, resistance is an extremely worrisome feature and that significantly worsens its therapeutic interventions. Bacterial resistance to the main in-use antimicrobials, particular…
The mycobacterium cell wall is a complex and highly regulated structure and proteins involved in its biosynthesis or remodelling can drive the balance between the cell elongation and the cell division. The enzymes involved in the assembly of this complex structure, which is constituted by peptidoglycan, arabinogalactan and mycolic acids, as well the enzymes responsible for its regulation …
Soil microorganisms are responsible for the production of a large number of antibiotics due to the highly competitive environment for space and nutrients. In addition, we can also use such molecules in the treatment of various illness, including infectious diseases and cancer. Several groups of antibiotics, such as aminoglycosides, changed completely the Medicine because to the benefits o…
(Only some records are available in English at this moment)
Infectious diseases are currently one of the significant problems in worldwide public health. Among them are those caused by invasive fungi, which lead to the death of a large number of patients, particularly those from hospital environments or those with immunosuppressed diseases. However, there are a few alternatives for treating these infections, but they still have significant side ef…
The principal therapeutic approach for treating bacterial infections is based on the use of antibacterial agents. One of the difficulties associated with this treatment is the development of resistance mechanisms. The search for new molecules that can circumvent these resistance mechanisms requires a global financial and public health effort. Given the need to develop strategies to overco…
(Only some records are available in English at this moment)
Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis and affects around 10 million people a year worldwide, making it one of the main causes of death from infections. The therapy used to treat tuberculosis is complex and requires at least three different relatively toxic drugs over a period of approximately 6 months, which makes it easier for patients to give up and …
Tuberculosis is a high-impact disease, diagnosed in 10.6 million patients and with a fatality rate of 1.3 million people in 2022 alone. The main drugs used to combat the disease are: isoniazid, rifampicin, ethambutol and pyrazinamide. Various studies have been carried out to understand the mechanism of action of these drugs, but there is no consensus on pyrazinamide (PZA). Two hypotheses …
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis that affects, approximately, 10 million people a year, and is one of the main causes of death by infections. The treatment of tuberculosis requires the use of at least three drugs that are relatively toxic to patients. As the ideal treatment regimen is approximately six months, individuals are likely to discon…
(Only some records are available in English at this moment)
The discovery of new specialized metabolites is vital in addressing the challenge posed by emerging superbugs and drug resistance. Soil and freshwater environments have fostered the evolution of microorganisms with unique adaptations, leading to the production of bioactive compounds with significant pharmacological potential. The genus Streptomyces has a rich history in antibiotic discove…
The development of new molecules aiming at treating infections caused by resistant pathogens is a challenging path. Strategies to improve existing compounds or discover new ones require a lot of effort and, especially, time. There are difficulties in not only isolating a new compound but also finding interesting chemical modifications that could achieve efficiency in vivo. In this scenari…
As highlighted by recent global health reports, millions of deaths annually occur from bacterial infections. Although there is a broad availability of antimicrobial agents, the growing resistance of bacteria to these treatments is becoming an increasingly public health problem. Therefore, the development of new antimicrobial agents is critical. Type II topoisomerases have proven to be eff…
Among the main drugs used to treat tuberculosis, isoniazid (INH) is considered a first-line drug and fluoroquinolones (FQL), mainly Moxifloxacin (MFX), are gaining space in the most current treatment regimens. Particularly, for INH and MFX, their targets, which include the enzymes InhA encoded by inhA gene, and DNA gyrase, encoded by gyrA and GryB genes, respectively, have the characteris…
Natural products represent an important source of bioactive materials for medical and veterinary use. Although the field of biological chemistry has had considerable advances in knowledge of these compounds, there is still a lack of understanding of the underlying mechanisms of their biogenesis. An important class of natural products includes polyketides, which are molecules that have dis…
(Only some records are available in English at this moment)